Tufts Postdoc Merges Computer Science with Alpaca Antibody Research in Innovative Study

Will White, a postdoctoral scholar in Tufts University's Department of Computer Science, has redirected his bioengineering training toward an unexpected collaboration with the alpaca immune system. After earning both a bachelor’s degree and a Ph.D. focused on molecular biology, White originally expected a career centered on DNA, proteins, and conventional wet‑lab work. Instead, his newest project fuses algorithmic design with the distinctive traits of alpaca antibodies, forging a fresh interdisciplinary avenue.

Alpacas generate single‑chain antibodies called nanobodies, valued for their robustness and amenability to engineering. White’s research employs machine‑learning methods to forecast nanobody structures and enhance their binding strengths to therapeutic targets. By inputting extensive datasets of alpaca immune repertoires into computational models, the team seeks to hasten a design process that normally consumes months of lab‑based trial and error.

The effort mirrors a wider shift in computational biology that is redefining drug‑discovery strategies. Conventional approaches depend heavily on labor‑intensive, trial‑and‑error protein screening, a practice that is both time‑consuming and expensive. White’s strategy capitalizes on high‑performance computing to simulate molecular interactions, potentially compressing the timeline from concept to candidate molecule.

University representatives point out that the partnership highlights Tufts’ dedication to cross‑departmental investigation. The computer‑science unit contributes expertise in algorithm creation and data management, while the bioengineering faculty supplies deep insight into immunology and protein chemistry. This collaboration enables the project to tackle questions that lie at the nexus of two traditionally distinct disciplines.

Looking forward, White intends to corroborate his computational forecasts with a series of laboratory assays, working alongside biotech companies interested in nanobody therapeutics. Should the approach prove successful, the workflow could become a model for applying artificial intelligence to other unconventional immune systems, expanding the arsenal available to drug developers. The work not only showcases the potential of interdisciplinary science but also underscores how seemingly obscure animal biology can drive cutting‑edge technological advances.